Avalo Therapeutics (AVTX) Cash from Operations (2014 - 2026)

Avalo Therapeutics has reported Cash from Operations for 13 years, with the latest figure at 17700000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 87.16% year-over-year to 17700000.0; the trailing twelve-month figure through Mar 2026 stood at 59743000.0 (down 14.21% YoY), and the FY2025 full-year result was 51500000.0, down 4.98% from the prior year.
• Cash from Operations for Q1 2026 stood at 17700000.0, down from 14288000.0 in the prior quarter.
• The five-year high for Cash from Operations was 5726000.0 in Q3 2022, with the low at 17700000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 10334529.41 across 5 years, with a median of 11390000.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 135.15% — and 2024, when it tumbled 443.89%.
• Avalo Therapeutics' Cash from Operations stood at 3940000.0 in 2022, then advanced by 29.8% to 2766000.0 in 2023, then plunged by 443.89% to 15044000.0 in 2024, then climbed by 5.03% to 14288000.0 in 2025, then fell by 23.88% to 17700000.0 in 2026.
• The last three Cash from Operations figures came in at 17700000.0 (Q1 2026), 14288000.0 (Q4 2025), and 16365000.0 (Q3 2025), per Business Quant data.